menu

How Do We Implement ANNEXXa-I Into Our Clinical Practice?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

How Do We Implement ANNEXXa-I Into Our Clinical Practice?

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Join us as expert faculty, Dr. Adam Brufsky and Dr. Christopher Gallagher, discuss the qualities of credible real world evidence (RWE) publications, application of CDK4/6 inhibitor RWE in hormone receptor positive metastatic breast cancer, and integrating RWE into everyday clinical decision and shared decision making conversations. This 15-minute activity provides a practical discussion to increase clinician familiarity and comfort with RWE of CDK4/6 inhibitors in metastatic breast cancer and clinicians’ confidence in their ability to discuss RWE with their patients.

  • Faculty Disclosure

    Adam Brufsky, MD, PhD, faculty for this educational event, is a contracted researcher for AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, and Myriad. 

    Christopher M Gallagher, MD, faculty for this educational event, is a contracted researcher for AstraZeneca, Lilly Oncology, Daiichi Sankyo; and receives consulting fees from AstraZeneca, Lilly Oncology, and Daiichi Sankyo. 

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, nurses, and pharmacists, as well as other clinicians involved in the management of patients with HR+/HER2-metastatic breast cancer (MBC).

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer Inc.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Join us as expert faculty, Dr. Adam Brufsky and Dr. Christopher Gallagher, discuss the qualities of credible real world evidence (RWE) publications, application of CDK4/6 inhibitor RWE in hormone receptor positive metastatic breast cancer, and integrating RWE into everyday clinical decision and shared decision making conversations. This 15-minute activity provides a practical discussion to increase clinician familiarity and comfort with RWE of CDK4/6 inhibitors in metastatic breast cancer and clinicians’ confidence in their ability to discuss RWE with their patients.

  • Faculty Disclosure

    Adam Brufsky, MD, PhD, faculty for this educational event, is a contracted researcher for AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma, and Myriad. 

    Christopher M Gallagher, MD, faculty for this educational event, is a contracted researcher for AstraZeneca, Lilly Oncology, Daiichi Sankyo; and receives consulting fees from AstraZeneca, Lilly Oncology, and Daiichi Sankyo. 

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, nurses, and pharmacists, as well as other clinicians involved in the management of patients with HR+/HER2-metastatic breast cancer (MBC).

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Commercial Support

    This activity is supported by an independent educational grant from Pfizer Inc.

Facebook Comments

Schedule26 May 2024